Can we really predict risk of cancer?

Cancer Epidemiology

Volumn 37, Issue 4, 2013, Pages 349-352

  Thrift, Aaron P ^a   Whiteman, David C ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Esophageal neoplasms; Neoplasms; Risk assessment; Risk factors; Risk reduction behavior

Indexed keywords

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COLORECTAL CANCER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ADENOCARCINOMA; ALGORITHMS; DECISION MAKING; ESOPHAGEAL NEOPLASMS; HUMANS; MODELS, STATISTICAL; NEOPLASMS; POLICY MAKING; RISK ASSESSMENT; RISK FACTORS;

EID: 84878906803     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.04.002     Document Type: Review

References (65)

1. Cooney M.T., Dudina A., D'Agostino R., Graham I.M. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?. Circulation 2010, 122:300-310.
2. Moons K.G., Kengne A.P., Woodward M., Royston P., Vergouwe Y., Altman D.G., et al. Risk prediction models. I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012, 98:683-690.
3. Moons K.G., Kengne A.P., Grobbee D.E., Royston P., Vergouwe Y., Altman D.G., et al. Risk prediction models. II. External validation, model updating, and impact assessment. Heart 2012, 98:691-698.
4. Steyerberg E.W. Clinical prediction models: a practical approach to development, validation and updating 2009, Springer, New York.
5. Freedman A.N., Seminara D., Gail M.H., Hartge P., Colditz G.A., Ballard-Barbash R., et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005, 97:715-723.
6. Moons K.G., Royston P., Vergouwe Y., Grobbee D.E., Altman D.G. Prognosis and prognostic research: what, why, and how?. Br Med J 2009, 338.
7. Kannel W.B., McGee D., Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976, 38:46-51.
8. Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008, 118:2243-2244.
9. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
10. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., May M., Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Br Med J 2007, 335:136-141.
11. Woodward M., Brindle P., Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007, 93:172-176. SIGN group on risk estimation.
12. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002, 105:310-315.
13. National Vascular Disease Prevention Alliance Guidelines for the assessment of absolute cardiovascular disease risk 2009, National Heart Foundation of Australia, Canberra.
14. New Zealand Guidelines Group Best practice evidence-based guideline: the assessment and management of cardiovascular risk 2003, NZGG, Wellington.
15. Wood D., Wray R., Poulter N., Williams B., Kirby M., Patel V., et al. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91:v1-v52.
16. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
17. Cooper A., O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. Br Med J 2008, 336:1246-1248. Guideline Development Group.
18. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003, 24:1601-1610.
19. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012, 33:1635-1701.
20. Scottish Intercollegiate Guidelines Network Risk estimation and the prevention of cardiovascular disease. A national clinical guideline 2007, SIGN, Edinburgh.
21. Jackson R. Cardiovascular risk prediction: are we there yet?. Heart 2008, 94:1-3.
22. Eichler K., Zoller M., Tschudi P., Steurer J. Barriers to apply cardiovascular prediction rules in primary care: a postal survey. BMC Fam Pract 2007, 8:1.
23. van Steenkiste B., van der Weijden T., Stoffers H., Grol R. Barriers to implementing cardiovascular risk tables in routine general practice. Scand J Prim Health Care 2004, 22:32-37.
24. Marshall T. Estimating the value of information in strategies for identifying patients at high risk of cardiovascular disease. Inform Prim Care 2006, 14:85-92.
25. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879-1886.
26. Costantino J.P., Gail M.H., Pee D., Anderson S., Redmond C.K., Benichou J., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999, 91:1541-1548.
27. Anothaisintawee T., Teerawattananon Y., Wiratkapun C., Kasamesup V., Thakkinstian A. Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Res Treat 2012, 133:1-10.
28. Meads C., Ahmed I., Riley R.D. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 2012, 132:365-377.
29. Wacholder S., Hartge P., Prentice R., Garcia-Closas M., Feigelson H.S., Diver W.R., et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010, 362:986-993.
30. National Cancer Institute. The nation's investment in cancer research. A plan and budget proposal for the fiscal year 2006. Available from: [accessed 18.02.13]. http://www.cancer.gov/aboutnci/budget_planning_leg/plan-archives.
31. Win A.K., MacInnis R.J., Hopper J.L., Jenkins M.A. Risk prediction models for colorectal cancer: a review. Cancer Epidemiol Biomarkers Prev 2012, 21:398-410.
32. Williams L.H., Barlow W.E., Shors A.R., Solomon C., White E. Identifying persons at highest risk of melanoma using self-assessed risk factors. J Clin Exp Dermatol Res 2011, 2.
33. Fortes C., Mastroeni S., Bakos L., Antonelli G., Alessandroni L., Pilla M.A., et al. Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev 2010, 19:393-400.
34. Fears T.R., Guerry D., Pfeiffer R.M., Sagebiel R.W., Elder D.E., Halpern A., et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006, 24:3590-3596.
35. Mar V., Wolfe R., Kelly J.W. Predicting melanoma risk for the Australian population. Australas J Dermatol 2011, 52:109-116.
36. Cho E., Rosner B.A., Feskanich D., Colditz G.A. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005, 23:2669-2675.
37. Hoggart C., Brennan P., Tjonneland A., Vogel U., Overvad K., Ostergaard J.N., et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila Pa) 2012, 5:834-846.
38. Tammemagi C.M., Pinsky P.F., Caporaso N.E., Kvale P.A., Hocking W.G., Church T.R., et al. Lung cancer risk prediction: Prostate, Lung Colorectal and Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011, 103:1058-1068.
39. Spitz M.R., Hong W.K., Amos C.I., Wu X., Schabath M.B., Dong Q., et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007, 99:715-726.
40. Cassidy A., Myles J.P., van Tongeren M., Page R.D., Liloglou T., Duffy S.W., et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008, 98:270-276.
41. Bach P.B., Kattan M.W., Thornquist M.D., Kris M.G., Tate R.C., Barnett M.J., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003, 95:470-478.
42. Wen C.P., Lin J., Yang Y.C., Tsai M.K., Tsao C.K., Etzel C., et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 2012, 104:1599-1611.
43. Michikawa T., Inoue M., Sawada N., Iwasaki M., Tanaka Y., Shimazu T., et al. Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. Prev Med 2012, 55:137-143.
44. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006, 98:529-534.
45. Nam R.K., Toi A., Klotz L.H., Trachtenberg J., Jewett M.A., Appu S., et al. Assessing individual risk for prostate cancer. J Clin Oncol 2007, 25:3582-3588.
46. Smith R.A., Cokkinides V., Brooks D., Saslow D., Shah M., Brawley O.W. Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2011, 61:8-30.
47. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
48. Amir E., Freedman O.C., Seruga B., Evans D.G. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010, 102:680-691.
49. Thrift A.P., Kendall B.J., Pandeya N., Whiteman D.C. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013, 11:138-144.
50. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005, 97:142-146.
51. Thrift A.P., Whiteman D.C. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012, 23:3155-3162.
52. Gavin A.T., Francisci S., Foschi R., Donnelly D.W., Lemmens V., Brenner H., et al. Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol 2012, 36:505-512.
53. Reid B.J., Li X., Galipeau P.C., Vaughan T.L. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010, 10:87-101.
54. Lagergren J., Bergstrom R., Lindgren A., Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-831.
55. Dent J., El-Serag H.B., Wallander M.A., Johansson S. Epidemiology of gastrooesophageal reflux disease: a systematic review. Gut 2005, 54:710-717.
56. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307:491-497.
57. The Information Centre Statistics on obesity, physical activity and diet: England, 2013 2013, The Information Centre, London.
58. Centers for Disease Control and Prevention Current Cigarette Smoking Among Adults - United States, 2011. MMWR Morb Mortal Wkly Rep 2011, 61:889-894.
59. Office for National Statistics. General lifestyle survey overview: a report on the 2010 general lifestyle survey; 2012.
60. Whiteman D.C., Sadeghi S., Pandeya N., Smithers B.M., Gotley D.C., Bain C.J., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008, 57:173-180.
61. Ware J.H. The limitations of risk factors as prognostic tools. N Engl J Med 2006, 355:2615-2617.
62. Wald N.J., Hackshaw A.K., Frost C.D. When can a risk factor be used as a worthwhile screening test?. Br Med J 1999, 319:1562-1565.
63. Aschard H., Chen J., Cornelis M.C., Chibnik L.B., Karlson E.W., Kraft P. Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases. Am J Hum Genet 2012, 90:962-972.
64. Janssens A.C., van Duijn C.M. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008, 17:R166-R173.
65. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J 1981, 282:1847-1851.